PCSK9 and coronary artery disorder: In patients with stable coronary artery disease (CAD) and elevated lipoprotein a in serum showed a notable decrease in miR-191-5p expression and elevated miR-224-5p and miR-483-5p expression levels in patients compared to control subjects, with miR-483-5p expression significantly predicting baseline serum PCSK9 levels [56].